Regeneron Pharmaceuticals (REGN) EPS (Weighted Average and Diluted) (2010 - 2026)
Regeneron Pharmaceuticals' quarterly EPS (Weighted Average and Diluted) came in at $6.75 in Q1 2026, down 7.15% year-on-year from $7.27 in Q1 2025, and down 14.23% quarter-over-quarter from $7.87 in Q4 2025.
Regeneron Pharmaceuticals has reported EPS (Weighted Average and Diluted) for 17 years, with the latest figure at $6.75 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) fell 7.15% year-over-year to $6.75; the trailing twelve-month figure through Mar 2026 stood at $41.05 (up 4.37% YoY), and the FY2025 full-year result was $41.48, up 8.19% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at $6.75, down from $7.87 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $13.62 in Q3 2025, with the low at $6.27 in Q1 2024.
- Average EPS (Weighted Average and Diluted) over 5 years is $9.39, with a median of $8.61 recorded in 2022.
- Year-over-year, EPS (Weighted Average and Diluted) slumped 73.29% in 2022 and soared 46.0% in 2024.
- Tracing REGN's EPS (Weighted Average and Diluted) over 5 years: stood at $10.49 in 2022, then slipped by 2.76% to $10.2 in 2023, then dropped by 20.49% to $8.11 in 2024, then slipped by 2.96% to $7.87 in 2025, then retreated by 14.23% to $6.75 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at $6.75 (Q1 2026), $7.87 (Q4 2025), and $13.62 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | -2.29 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.75 |
| Dec 31, 2025 | 7.87 |
| Sep 30, 2025 | 13.62 |
| Jun 30, 2025 | 12.81 |
| Mar 31, 2025 | 7.27 |
| Dec 31, 2024 | 8.11 |
| Sep 30, 2024 | 11.54 |
| Jun 30, 2024 | 12.41 |
| Mar 31, 2024 | 6.27 |
| Dec 31, 2023 | 10.20 |
| Sep 30, 2023 | 8.89 |
| Jun 30, 2023 | 8.50 |
| Mar 31, 2023 | 7.17 |
| Dec 31, 2022 | 10.49 |
| Sep 30, 2022 | 11.66 |
| Jun 30, 2022 | 7.47 |
| Mar 31, 2022 | 8.61 |
| Dec 31, 2021 | 19.68 |
| Sep 30, 2021 | 14.33 |
| Jun 30, 2021 | 27.97 |
| Mar 31, 2021 | 10.09 |
| Dec 31, 2020 | 10.24 |
| Sep 30, 2020 | 7.39 |
| Jun 30, 2020 | 7.61 |
| Mar 31, 2020 | 5.43 |
| Dec 31, 2019 | 6.93 |
| Sep 30, 2019 | 5.86 |
| Jun 30, 2019 | 1.68 |
| Mar 31, 2019 | 3.99 |
| Dec 31, 2018 | 7.15 |
| Sep 30, 2018 | 5.17 |
| Jun 30, 2018 | 4.82 |
| Mar 31, 2018 | 4.16 |
| Dec 31, 2017 | 1.50 |
| Sep 30, 2017 | 3.32 |
| Jun 30, 2017 | 3.34 |
| Mar 31, 2017 | 2.16 |
| Dec 31, 2016 | 2.19 |
| Sep 30, 2016 | 2.27 |
| Jun 30, 2016 | 1.69 |
| Mar 31, 2016 | 1.59 |
| Dec 31, 2015 | 1.34 |
| Sep 30, 2015 | 1.82 |
| Jun 30, 2015 | 1.69 |
| Mar 31, 2015 | 0.66 |
| Dec 31, 2014 | 0.78 |
| Sep 30, 2014 | 0.73 |
| Jun 30, 2014 | 0.85 |
| Mar 31, 2014 | 0.61 |
| Dec 31, 2013 | 0.86 |
| Sep 30, 2013 | 1.25 |
| Jun 30, 2013 | 0.79 |
| Mar 31, 2013 | 0.90 |
| Dec 31, 2012 | 4.08 |
| Sep 30, 2012 | 1.72 |
| Jun 30, 2012 | 0.70 |
| Mar 31, 2012 | 0.11 |
| Dec 31, 2011 | -0.58 |
| Sep 30, 2011 | -0.68 |
| Jun 30, 2011 | -0.69 |
| Mar 31, 2011 | -0.49 |
| Dec 31, 2010 | -0.18 |